Diagnostic potential of phosphorylated cardiac troponin I as a sensitive, cardiac-specific marker for early acute coronary syndrome: preliminary report.
Cardiac troponin I (cTnI) has low sensitivity in the early hours of acute coronary syndrome (ACS). For patients with early ACS symptoms, we determined the diagnostic potential of an immunoassay for phosphorylated cTnI (PO(4)-cTnI). In a prospective study of 61 emergency department patients with suspected ACS, we compared a novel plasma immunoassay for PO(4)-cTnI to cTnI overall and in a subgroup with symptoms < or =4 h duration (n = 31). Admission PO(4)-cTnI and cTnI assays (thresholds determined by ROC curve) were analyzed in a blinded fashion against the clinical, ECG and coronary angiographic diagnosis of ACS. Overall, PO(4)-cTnI sensitivity was significantly higher than cTnI (82% vs. 50%, respectively, P < 0.05) and PO(4)-cTnI specificity was 81% (n = 61). Addition of PO(4)-cTnI to cTnI improved sensitivity to 91% vs. 50% for cTnI alone (P < 0.001). In the < or =4 h subgroup (n = 31), PO(4)-cTnI sensitivity was significantly higher than cTnI (79% vs. 26%, respectively, P < 0.01) and PO(4)-cTnI specificity was 75%. In the same < or =4 h subgroup, addition of PO(4)-cTnI to cTnI improved sensitivity to 84% vs. 26% for cTnI alone (P = 0.001). The results suggest that PO(4)-cTnI, alone or in combination with cTnI, warrants further investigation as a sensitive, cardiac-specific diagnostic tool for early ACS.